MedTrace Logo

Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

NCT03697668 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-10-05

No results posted yet for this study

Summary

The purpose of this study is to provide a new drug combination for a better treatment of P. falciparum for a faster parasite clearance and to counteract artemisinin resistance.

Conditions

  • Plasmodium Falciparum Malaria (Drug Resistant)

Interventions

DRUG

Imatinib

triple combination for the treatment of malaria

DRUG

Dihydroartemisinin-piperaquine

standard malaria treatment

Sponsors & Collaborators

  • Università degli Studi di Sassari

    collaborator OTHER

  • Purdue University

    collaborator OTHER

  • Vinmec Healthcare System

    collaborator OTHER

  • Nurex S.r.l.

    lead INDUSTRY

Principal Investigators

  • Huynh D Chien, MD, PhD · UNIVERSITY OF HUE, VIETNAM AND VINMEC DANANG INTERNATIONAL HOSPITAL, Hai Chau, Danang.

  • Francesco M Turrini, MD, PhD · University of Turin, Italy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-17
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697668 on ClinicalTrials.gov